{"id":"tjo-087","brandName":"TJO-087","genericName":"TJO-087","companyId":"taejoon-pharmaceutical-co-ltd","companyName":"Taejoon Pharmaceutical Co., Ltd.","phase":"phase_3","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"TJO-087 is a novel therapeutic candidate in Phase 3 development by Taejoon Pharmaceutical for moderate to severe dry eye disease. The drug aims to address unmet needs in this condition, with a focus on improving patient outcomes and safety.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TJO-087 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.","oneSentence":"TJO-087 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"trials":[],"indications":{"approved":[{"name":"Type 2 diabetes"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}